Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial
The maximum tolerated dose (MTD) of lobaplatin as a single agent chemotherapy concurrent with intensity-modulated radiotherapy (IMRT) in Asian population with nasopharyngeal carcinoma (NPC) remains unclear. From June 2016 to December 2017, 17 patients diagnosed with stage III-IVb NPC from an Asian p...
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
Elsevier
2018-08-01
|
| Col·lecció: | Translational Oncology |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1936523318301852 |